As their CKD worsens, T2D patients become contraindicated for metformin, and 2 out of every 3 patients with advanced CKD use insulin for glucose control. Relying on insulin brings increased risk of hypoglycemia and cardiovascular complications in the growing T2D/CKD populatio ...

Excited that members of the #Anjiverse will be attending #BIOEurope 2022 in person! Reach out to Ulla Rauh or Chloe Kamps to explore ways to work together. #begoodpartners

We’re thrilled to announce that Anji and Population Health Partners have entered into a strategic collaboration to accelerate development of our two lead clinical assets ANJ900 (delayed-release #metformin) and ANJ908 (pradigastat).Read more here bwnews.pr/3TeTzIS #T2D #CKD

A recent @PhreesiaLifeSci report surveyed almost 7,000 patients diagnosed with or treated for constipation and found that 62% of patients felt their disease had a moderate or great impact on their daily life: bit.ly/3TKdEab

Have you tried our #AmericanDiabetesMonth quiz this week? Be sure to check back on Monday for the answer and the next question in the series

ANSWER: 75% From 2005 to2016, first-line use of #metformin increased from 60 to 77% in the U.S. In 2020, metformin was prescribed to over 92 million patients in the U.S., making it the 3rd most widely prescribed medication. bit.ly/3WM7QPc

2nd question in our #AmericanDiabetesMonth quiz: How many people with diabetes also suffer from chronic kidney disease?

ANSWER: 1 in 3 Chronic kidney disease is common in people with Type 2 diabetes. Approximately 1 in 3 adults with diabetes has CKD, and 1 in 8 of T2D patients aged 65 and above have progressed to CKD3B stage. For more info: bit.ly/3z9X4s5 and bit.ly/3DoxJfb

We are halfway through our #AmericanDiabetesMonth quiz! Question 3: Current treatment guidelines recommend a reduction in metformin dose for T2D patients at what stage of chronic kidney disease?

ANSWER: All of the above T2D patients with impaired kidney function are advised to lower their metformin dose or discontinue use. Without access to full metformin, patients with CKD3B are more than 2x more likely to use insulin to manage their glucose bit.ly/3SSVulx

Final question in our #AmericanDiabetesMonth quiz! Metformin augments the glucose-lowering effects of which T2D medication:

ANSWER: All of the above Metformin can boost effects of common oral drugs that promote insulin secretion (sulfonyl ureas, GLP-1 RAs) or glucose excretion (SGLT2 inhibitors). But in patients with reduced kidney function, metformin might not be available bit.ly/3udxHm5

Based on recent literature highlighting #metformin’s action to the gut, Anji is developing a delayed release formulation called ANJ900 which minimizes metformin absorption and potentially offers a safer treatment option for #T2D patients with advanced #CKD #AmericanDiabetesMonth

We are excited to share that Ming Yang has been promoted to Senior Medical Director. Ming has played a key role in our clinical development strategies as well as the expansion of our pipeline. Congratulations, Ming! #Anjiverse

At Anji, we strive to build bridges to connect the team across the globe. This fall the #Anjiverse challenged each other to “walk the world”, collectively traveling almost 5,000 km visiting landmarks from Berlin to Shanghai to Boston. Congratulations team!

At Anji, we are committed to giving back to our communities around the world. In November, the #Anjiverse participated in the first annual Month of Giving to make a #GlobalImpact. Congratulations to the team!

Happy holidays from the #Anjiverse! We’re closing out 2022 with great momentum – thank you to our wonderful team and network of partners who help in our mission to improve lives globally, and we’re excited to see all that is to come in 2023!

Our CEO Brian Hubbard shares his thoughts on the #BioPharma funding environment in part 1 of the “Scrip Asks...What Does 2023 Hold For Biopharma?” series from Scrip, Citeline Commercial's Editor-in-Chief Eleanor Malone. Check out the article here: bit.ly/3Qu0bCx